键凯科技公告，股东吴凯庭因自身资金需求，计划自披露起15个交易日后的3个月内，即2025年10月9日 至2026年1月8日，通过大宗交易方式减持公司股份不超过121.3万股，占公司总股本的2%；截至公告日 其持股914.58万股，占15.08%，所持股份来源为IPO前取得。 ...

2025 年 9 月 北京键凯科技股份有限公司 2025 年第一次临时股东大会会议资料 目录 证券代码：688356 证券简称：键凯科技 北京键凯科技股份有限公司 2025 年第一次临时股东大会 会议资料 | 2025 年第一次临时股东大会会议须知 | 3 | | --- | --- | | 2025 年第一次临时股东大会会议议程 | 6 | | 议案一：《关于取消监事会并修订<公司章程>的议案》 8 | | | 议案二：《关于修订和制定部分公司内部管理制度的议案》 | 9 | | 议案三：《关于补选公司独立董事的议案》 | 11 | 2 北京键凯科技股份有限公司 2025 年第一次临时股东大会会议资料 北京键凯科技股份有限公司 2025 年第一次临时股东大会会议须知 为维护全体股东的合法权益，确保股东大会会议秩序和议事效率，保证股东 大会的顺利召开，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）以及《北京键凯科技股份有限公 司章程》（以下简称"《公司章程》"）和《北京键凯科技股份有限公司股东大会议 事规则》等有关规定，特制定北京键凯科技股份有限公 ...

Group 1 - The innovative drug concept stocks are experiencing significant activity, with Jimin Health hitting the daily limit up [1] - JianKai Technology has seen an increase of over 10% [1] - Other companies such as YueKang Pharmaceutical, NuoSiGe, QianYan Bio, XinLiTai, and Chengdu XianDao are also following the upward trend [1]

Investment Rating - The report maintains a "Buy" rating for the company, considering the significant growth in overseas revenue and the promising application space for its drug and medical device projects [4]. Core Insights - The company is undergoing a performance transformation period, with orderly progress in new drug and medical beauty projects. In H1 2025, the company achieved operating revenue of 130 million yuan, a year-on-year increase of 0.89%, while the net profit attributable to the parent company was 22 million yuan, a decrease of 21.08% [1][4]. - Domestic sales have decreased while exports have increased. The main business revenue remained stable compared to the same period last year, with product sales revenue at 125.56 million yuan, down 0.26% year-on-year, and technical service revenue at 3.78 million yuan, up 83.77% year-on-year. Domestic sales revenue was 20.48 million yuan, down 58.35%, while export revenue was 105.08 million yuan, up 36.96% [2][3]. Summary by Sections Financial Performance - In H1 2025, the company reported a total R&D investment of 42.60 million yuan, an increase of 52.44% year-on-year, with R&D investment accounting for 32.84% of operating revenue, up 11.11 percentage points year-on-year. The company is advancing its clinical trials for new drugs and has received regulatory approvals for its medical beauty devices [3][4]. Profit Forecast and Valuation - The profit forecast for the company remains at 53 million yuan for 2025, 124 million yuan for 2026, and 172 million yuan for 2027. The report highlights the potential for significant growth in overseas revenue and the development of its drug and device pipeline [4][10].

Core Viewpoint - JianKai Technology (688356) reported a revenue increase but a profit decline in its 2025 mid-year financial report, indicating potential challenges in profitability despite stable revenue growth [1] Financial Performance - Total revenue reached 130 million yuan, a year-on-year increase of 0.89% - Net profit attributable to shareholders was 22.05 million yuan, a year-on-year decrease of 21.08% - In Q2, total revenue was 60.62 million yuan, a year-on-year decline of 4.97% - Q2 net profit attributable to shareholders was 10.17 million yuan, a year-on-year decrease of 24.6% [1] Profitability Metrics - Gross margin stood at 59.47%, down 11.42% year-on-year - Net margin was 17.0%, down 21.77% year-on-year - Total selling, administrative, and financial expenses amounted to 28.43 million yuan, accounting for 21.91% of revenue, a decrease of 2.08% year-on-year - Earnings per share were 0.36 yuan, a year-on-year decrease of 21.74% [1] Return on Investment - The company's Return on Invested Capital (ROIC) was 2.25%, indicating weak capital returns - Historical median ROIC since listing is 15.77%, with the worst year being 2024 at 2.25% [2] Debt and Cash Flow - The company has a healthy cash asset position - The operating cash flow per share was 0.13 yuan, a significant year-on-year decrease of 88.23% [3] Accounts Receivable - The accounts receivable to profit ratio reached 276.46%, suggesting potential issues with cash collection [4] Fund Holdings - The largest fund holding JianKai Technology is JinXin Value Selected Mixed A, which has reduced its holdings to 35,400 shares - The fund's current scale is 15 million yuan, with a recent net value increase of 0.55% and a one-year increase of 114.48% [5]

Meeting Overview - The third supervisory board meeting of Beijing Jiankai Technology Co., Ltd. was held on August 27, 2025, with all three supervisors present, ensuring compliance with relevant laws and regulations [1]. Supervisory Board Resolutions - The supervisory board unanimously approved the 2025 semi-annual report, confirming that the report's preparation and review processes adhered to legal and internal regulations, accurately reflecting the company's financial status and operational results [1][2]. - The board also approved the proposal to cancel the supervisory board and amend the company's articles of association, aimed at enhancing corporate governance and aligning with the latest legal requirements [2][3]. - Additionally, the board agreed to the provision for asset impairment for the first half of 2025, stating that this decision aligns with the principle of prudence and relevant accounting standards, ensuring a true and fair representation of the company's financial condition [3].

Group 1 - The company will hold its shareholder meeting on September 17, 2025, at 14:00 in Beijing [1][4] - Voting will be conducted through a combination of on-site and online methods, with specific time slots for each [1][2] - The online voting system will be managed by the Shanghai Stock Exchange, with voting available from 9:15 to 15:00 on the day of the meeting [1][4] Group 2 - Shareholders registered by the close of trading on September 9, 2025, are eligible to attend the meeting [6] - The meeting will not provide gifts, and attendees will bear their own travel and accommodation costs [6] - The company has specified that no related shareholders need to abstain from voting [2]

Core Viewpoint - In the first half of 2025, JianKai Technology Co., Ltd. reported a slight increase in revenue but a significant decline in net profit, indicating challenges in domestic sales while experiencing growth in international orders [1][2]. Financial Performance - The company achieved operating revenue of 130 million yuan, a year-on-year increase of 0.89% [1]. - Product sales revenue was 126 million yuan, a decrease of 0.26% year-on-year, while technical service revenue reached 3.78 million yuan, an increase of 83.77% [1]. - Domestic sales revenue fell to 20.48 million yuan, down 58.35% year-on-year, primarily due to a major domestic client reducing orders [1]. - International sales revenue increased to 105 million yuan, a growth of 36.96% year-on-year, driven by a rise in orders from overseas pharmaceutical clients [1]. - The net profit attributable to shareholders was 22.05 million yuan, a decline of 21.08% year-on-year, and the net cash flow from operating activities decreased by 88.22% [1]. Research and Development - Total R&D investment amounted to 42.60 million yuan, an increase of 52.44% year-on-year, with R&D expenses accounting for 32.84% of operating revenue, up 11.11 percentage points [2]. - The increase in R&D investment is attributed to the ongoing Phase III clinical trial for the PEG-Irinotecan project for small cell lung cancer, which began patient enrollment in September 2024 [2]. Operational Strategy - Despite a challenging global political and economic landscape and intensified competition in the domestic pharmaceutical raw materials sector, the company maintained a stable operational development [2]. - The company leveraged its unique advantages in PEG modification technology across multiple fields and optimized its production quality management system [2]. - JianKai Technology successfully accumulated a substantial reserve of overseas pharmaceutical orders, laying a solid foundation for future business development [2].

Group 1 - The company announced the resignation of independent director Wang Chunfei due to the completion of his six-year term, which will result in the independent director count falling below one-third of the total board members [3][4][5] - The board has proposed Lin Wen as a candidate for the independent director position, pending approval from the shareholders' meeting [4][5][6] - If elected, Lin Wen will also take on roles in the compensation and assessment committee, audit committee, and nomination committee [6][7] Group 2 - The company held its 13th meeting of the third board on August 27, 2025, where several key resolutions were passed, including the approval of the 2025 semi-annual report [14][15][16] - The board also approved the proposal to cancel the supervisory board and amend the company's articles of association to enhance governance structure [19][21][22] - The company plans to hold a temporary shareholders' meeting on September 17, 2025, to discuss the resolutions passed by the board [57][58][59] Group 3 - The company reported a provision for asset impairment of 4.2167 million yuan for the first half of 2025, which includes 3.5847 million yuan for asset impairment losses and 632,000 yuan for credit impairment losses [38][40][41] - The board's audit committee and supervisory board have both agreed that the provision for asset impairment is in line with accounting standards and reflects the company's financial status accurately [43][45]

Core Viewpoint - The announcement from JianKai Technology regarding the approval of the 2025 semi-annual report and its summary by the third board meeting indicates the company's ongoing commitment to transparency and governance [2] Group 1 - JianKai Technology's third board meeting approved multiple proposals, including the 2025 semi-annual report and its summary [2]